Cardio Diagnostics Holdings, Inc. has filed Post-Effective Amendment No. 2 to its Form S-1 Registration Statement with the SEC on August 30, 2024. This amendment incorporates the latest financial information from the company's Annual Report for 2023 and the Quarterly Report for the period ending June 30, 2024. The updated registration statement includes recent financials showing nominal revenue and net losses, details on the sales of unregistered securities, and updates on indemnification provisions for directors and officers. Cardio Diagnostics, known for its epigenetics-based clinical blood tests for coronary heart disease, is also developing tests for other conditions such as stroke and diabetes. The company has obtained CPT codes for its tests, which is crucial for insurance coverage. However, potential changes in FDA regulations...Show More

Cardio Diagnostics Holdings, Inc. has filed Post-Effective Amendment No. 2 to its Form S-1 Registration Statement with the SEC on August 30, 2024. This amendment incorporates the latest financial information from the company's Annual Report for 2023 and the Quarterly Report for the period ending June 30, 2024. The updated registration statement includes recent financials showing nominal revenue and net losses, details on the sales of unregistered securities, and updates on indemnification provisions for directors and officers. Cardio Diagnostics, known for its epigenetics-based clinical blood tests for coronary heart disease, is also developing tests for other conditions such as stroke and diabetes. The company has obtained CPT codes for its tests, which is crucial for insurance coverage. However, potential changes in FDA regulations for laboratory-developed tests could impact the company's operations. Cardio Diagnostics, which is establishing an internal CLIA laboratory, does not plan to issue cash dividends in the near future. Its common stock and warrants are traded on Nasdaq under the symbols 'CDIO' and 'CDIOW'. The company will not benefit financially from the current offering of shares and warrants by selling securityholders, but may gain future proceeds from the exercise of warrants and options for corporate purposes.